Treatment of Behcet’s disease by Davatchi, Fereydoun et al.
  
http://cdjournal.muk.ac.ir,    4 April 
 
42     Chron Dis J, Vol. 1, No. 1, Spring 2013 
 
 
Treatment of Behcet’s disease 
 
Fereydoun Davatchi1, Nasrin Moghimi2, Mohammad Mousavi3, Alimohammad Fatemi4 
 
1 Professor, Division of Rheumatology, Shariati Hospital AND Behcet’s Unit, Rheumatology Research Center, 
Tehran University of Medical Sciences, Tehran, Iran 
2 Assistant Professor, Department of Rheumatology, School of Medicine, Kurdistan University of Medical 
Sciences, Sanandaj AND Behcet’s Unit, Rheumatology Research Center, Tehran University of Medical Sciences, 
Tehran, Iran 
3 Assistant Professor, Department of Rheumatology, School of Medicine, Shahrekord University of Medical 
Sciences, Shahrekord AND Behcet’s Unit, Rheumatology Research Center, Tehran University of Medical 
Sciences, Tehran, Iran 
4 Assistant Professor, Department of Rheumatology, School of Medicine, Isfahan University of Medical Sciences, 
Isfahan AND Behcet’s Unit, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran 
 
Abstract 
Behcet’s disease is a systemic disease classified among vasculitides. Major manifestations are mucous 
membrane lesions (oral aphthosis and genital aphthosis), skin manifestations (pseudofolliculitis, erythema 
nodosum), ocular manifestations (uveitis, retinal vasculitis), joint manifestations, vascular lesions (small to large 
vessel thrombosis, aneurysm), gastrointestinal manifestations, orchiepididymitis, and some rare manifestations 
like cardiac, pulmonary, and renal impairment. Diagnosis is mainly clinical. The International Diagnosis Criteria for 
Behcet’s Disease may be of help. The gold standard of treatment for mucocutaneous lesions is colchicine. In 
refractory cases, levamisole, thalidomide, and dapsone may be of help. For major organ involvement like the eyes 
and the brain, immunosuppressive drugs and prednisolone are the gold standard. In refractory cases, biological 
agents are the last resort. For gastrointestinal manifestations, sulfasalazine and prednisolone are the first-line 
treatment. For vascular involvement, the first line treatment was anticoagulation, but recently it was shown that 
immunosuppressive drugs and prednisolone were confirmed to be the best. In all refractory cases and for all 
different organs, the last resort is biological agents. 
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Introduction1 
Behcet’s disease (BD) is a multisystemic disease 
classified among vasculitides.1-3 The main 
pathologic feature is leukocytoclastic vasculitis. 
The disease is mainly seen along the historical 
Silk Road, but can be seen nowadays all over the 
world with a prevalence going from 0.64 
(Yorkshire) to 300 (Turkey) per 100,000 
inhabitants.4-11 The prevalence in Iran was 
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estimated from 16 to 80 patients per 100,000 
inhabitants.12-14  
The men to women ratios are from 0.38 in the 
US15 and 0.63 to 1.00 in Korea16 to 3.40 in Saudi 
Arabia17 and 1.00 to 4.90 in Kuwait.18  
BD is a disease of the youth but can be seen 
at any age.3,10 The mean age goes from 40 years 
(Brazil) to 20.8 years (Ireland), but the majority 
of countries are between 25 and 30 years. In 
Iran, the mean age is 26 years with a standard 
deviation of 11.3. At the onset of the disease, 
the youngest was 1 year old and the oldest  
70 years.19  
Review Article 
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Clinical manifestations of the BD are 
dominated by mucous-membrane manifestations 
[oral aphthosis (OA), genital aphthosis (GA)], 
skin manifestations [pseudofolliculitis (PF), 
erythema nodosum (EN), skin aphthosis], and 
ocular manifestations [anterior uveitis (AU), 
posterior uveitis (PU), retinal vasculitis (RV)]. In 
Iran, OA was seen in 97.3% of patients with 95% 
confidence interval (95%CI) of 96.9-97.7%. GA 
was seen in 64.6% (95%CI: 63.4-64.7), PF in 54.5% 
(95%CI: 53.3-55.7), skin manifestations in 64.9% 
(95%CI: 63.7-66.1), ocular manifestations in 56.8% 
(95%CI: 55.6-58), EN in 22.5% (95%CI: 21.5-23.5), 
skin aphthosis in 7% (95%CI: 6.4-7.6), AU in 
41.2% (95%CI:40-42.4), joint manifestations in 
37.4% (95%CI: 36.2-38.6), cataract in 19.6% 
(95%CI: 18.6-20.6), mono-arthritis in 7.6%  
(95%CI: 7-8.2), PU in 44.9% (95%CI: 43.7-46.1), 
RV in 32.1% (95%CI: 31-33.2), arthralgia in 17.2% 
(95%CI: 16.3-18.1), oligo-arthritis in 16.8% 
(95%CI: 15.9-17.7), ankylosing spondylitis in 2% 
(95%CI: 1.7-2.3), neurological manifestations in 
3.7% (95%CI: 3.2-4.2), peripheral lesions in 0.3% 
(95%CI: 0.2-0.4), central manifestations in 3.5% 
(95%CI: 3.1-3.9), isolated headache in 7.9% 
(95%CI: 7.2-8.6), gastrointestinal manifestations in 
7.4% (95%CI: 6.8-8), gastroduodenitis in 2.4% 
(95%CI: 2-2.8), peptic ulcer in 1.3% (95%CI: 1-1.6), 
chronic diarrhea in 2.2% (95%CI: 1.8-2.6), 
rectorrhagia in 1% (95%CI: 0.8-1.2), abdominal 
pain and nausea in 1.9 (95%CI: 1.6-2.2), vascular 
involvement in 8.3% (95%CI: 7.6-9), phlebitis in 
5.7% (95%CI: 5.1-6.3), large vessel involvement in 
1.7% (95%CI: 1.4-2), superficial phlebitis in 2.2% 
(95%CI: 1.8-2.6), cardiac manifestations in 0.6% 
(95%CI: 0.4-0.8), pulmonary manifestations in 
0.9% (95%CI: 0.7-1.1), and epididymitis in 4.7% 
(95%CI: 4.2-5.2).19 
Laboratory findings in Iran19 were as: normal 
erythrocyte sedimentation rate (ESR < 20) in 
46.5% (95%CI: 45.3-47.7), ESR between 20 and 50 
in 32.6% (95%CI: 31.5-33.8), ESR between 51 and 
100 in 13.8% (95%CI: 13-14.6), and ESR superior 
to 100 in 1.3% (95%CI: 1-1.6). Abnormal urine 
sediment was seen in 12.2% (95%CI: 11.4-13.0) of 
patients. Proteinuria was detected in 2.2% 
(95%CI: 1.8-2.6), cast in 0.2% (95%CI: 0.1-0.3), 
and hematuria in 6.3% (95%CI: 5.7-6.9). Like 
most of BD symptoms, abnormal urine 
sediments were transient. Renal biopsy was 
done in 18 patients for persistent proteinuria 
(WHO type II: 3 cases, type III: 7 cases, type IV: 5 
cases, type V: 2 cases, and amyloidosis: 2 cases). 
Pathergy test was positive in 52.5% of patients 
(95%CI: 51.3-53.7). HLA-B5 was checked in 6261 
patients and was positive in 53.3% of them 
(95%CI: 52.1-52.1). HLA-B51 was checked in 
1534 patients, it was detected in 47.9% of them 
(95%CI: 45.2-50.4). HLA-B27 was checked in 
5933 patients, it was detected in 8.6% of them 
(95%CI: 7.9-9.3). 
Disease Classification: 98.3% of the patients in 
Iran were classified by the International Criteria 
for Behcet's Disease.19 Looking at previous criteria 
for Behcet's disease, the rate of classification 
(sensitivity) was 97.2% with the Iran Classification 
Tree, 86.3% with the Korean criteria, 86.1% with 
the Japanese revised criteria, 81.0% with Dilsen 
revised criteria, and 78.0% with the International 
Study Group (ISG) criteria.19    
BD progresses by repeated cycles of attacks 
and remissions. After the attack, the healing 
process starts and lasts for several days to 
several months. Then the remission occurs. 
However, it is not a definitive remission. A new 
attack will occurs after several days of remission 
to several months, or even years, and everything 
starts all over again. For short attacks, the 
healing is complete and the tissue or the 
involved organ returns to its pre-attack state 
without any sequel. If the healing process takes 
long, sequels may appear. Longer the healing 
process, more chance to get sequels. Sometimes, 
before the healing process completes, a new 
attack occurs, aggravating the precedent attack. 
This is what usually happens with ocular 
lesions, where from one attack to another, 
lesions accumulate and progress toward severe 
loss of vision or blindness. In the past, the 
majority of BD patients with ocular lesions 
became blind in few years. Benezra and Cohen 
said in the past that after 10 years 74% of ocular 
  
 
http://cdjournal.muk.ac.ir,    4 April 
 
44     Chron Dis J, Vol. 1, No. 1, Spring 2013 
 
Treatment of Behcet’s disease Davatchi et al. 
involvement of BD lead to the loss of useful 
vision, no matter what treatment was used.20 
However, this is no more the case.21 
Treatment 
The aim of the treatment in BD is to accelerate 
the healing process and to prevent from sequels. 
If possible, it has to maintain the remission by 
preventing from new attacks. There are two 
categories of lesions. 
The first category comprises those 
manifestations that produce some burden 
without serious complications (e.g. 
mucocutaneous or many types of joint 
manifestations). These lesions do not require 
aggressive treatment, because complete healing 
is not indispensable and usually a shorter 
healing time with longer remission period will 
suffice. Not all patients in this group need 
treatment, especially those with very mild 
manifestations of short duration and long 
remission. In this group, colchicine is the first 
line, followed by levamisole, thalidomide, 
dapson, and non-steroidal anti-inflammatory 
drugs (NSAID) are the mainstay.  
The second group of lesions comprises those 
producing major morbidities. Among them are 
ocular lesions, as seen before, neurological 
manifestations, major vascular lesions (large 
vessel thrombosis, aneurysm), and the rare 
cardiopulmonary lesions. This group needs 
aggressive and early treatment. For them, 
immunosuppressive drugs, whether in mono 
therapy or combination therapy, associated to 
corticosteroids, is the first line treatment. In 
resistant cases biologic agents will be of help. 
Both groups may benefit of symptomatic or 
local treatments. 
Colchicine 
Colchicine is the first line treatment for 
mucocutaneous lesions of BD. It was first used 
in 1977 by Mizushima22 and Haim and 
Friedman-Birnbaum.23 Its efficacy raised some 
polemics, especially after the surveys of Aktulga 
et al.24 and Yurdakul et al.25 despite several case 
reports attesting its efficacy.26-31 A double blind 
control study of colchicine versus placebo, by 
Davatchi et al. showed its efficacy for 
mucocutaneous lesions and mild forms of joint 
involvement.32 The starting dose is 1 mg daily, 
taken at night. In some resistant cases it may be 
raised to 1.5 to 2 mg daily. Side effects are rare, 
mainly in the form of diarrhea especially in 
those taking more than 1 mg daily. In very rare 
cases, abnormality of liver function tests (LFT) 
as elevation of hepatic enzymes can be seen, 
necessitating the discontinuation of colchicine if 
the abnormal LFT persists. However, in the 
study of Davatchi et al., side effects were the 
same in the colchicine and the placebo group, 
with no statistically significant difference 
between them.32 
Colchicine has to be continued for longtime. 
Its discontinuation will result in the return of 
attacks to their original state (rate of recurrence 
and duration). 
Levamisole 
It is an immunomodulatory drug first used by 
Hamza and Ben in Tunisia.33 It was followed by 
de Merieux et al.34 who used it in 11 patients. 
More reports came later by Hamza et al.,35 and 
Davatchi et al.36 The indication is like colchicine, 
but for patients not responding to it.37 Side effect 
is classically agranulocytosis. Therefore, regular 
CBC has to be done to discover it. We never 
observe it.36 The same was for de Merieux et al.34 
The classic dose is 150 mg daily, 3 consecutive 
days per week. Upon good results, the dose may 
be decreased to two or one day per week. 
Levamisole was rather forgotten in the past 
decades; but a new report from Sun et al. 
opened new insight into the mechanism of the 
drug and its benefits in concomitant use with 
colchicine. They observed a significant decrease 
of interleukin-6 (IL-6), interleukin-8 (IL-8), and 
tumor necrosis factor alpha (TNF-α) in 64 
patients with mucocutaneous lesions.38     
Thalidomide 
It is an experimental drug used in resistant cases 
of BD.1 It is not for daily or routine use.2 It was 
used for all kinds of manifestations.39 The main 
indication is mucocutaneous manifestations 
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resistant to other treatments.40 The treatment 
starts with 200 mg daily. As soon as possible, 
upon the remission of symptoms, the dose is 
decreased to 100 mg daily, and if possible to  
50 mg as the maintenance dose.39 The safe dose, 
without side effects, would be 50 mg taken at 
night, 3 nights per week.40 Side effects are mainly 
peripheral neuropathy and drowsiness. In difficult 
cases, the classical dose still can be used 
monitoring closely the neuropsychological 
manifestations.41 Later, a double-blind, controlled 
study demonstrated the effectiveness of 
thalidomide in the treatment of mucocutaneous 
lesions of BD.42 Sayarlioglu et al. used it 
successfully in a case of intestinal perforation not 
responding to Immunosuppressive drugs.43 
Thalidomide has been lately shown to be not only 
an anti-inflammatory drug, but also an 
immunoregulatory drug by decreasing the TNF-α 
receptor levels, cluster of differentiation 8 
(CD8)/CD11b+ and CD16/CD56+ cells. On the 
other hand CD4+CD45RO+ T cells and 
gammadelta+ T cells increased after treatment.44  
Dapson 
It is an anti-leprotics agent used in resistant 
cases of mucocutaneous lesions successfully.45 
Not all authors agree with its efficacy in all 
resistant cases.46 It is used as 50-100 mg daily. 
Side effects are hemolysis, liver toxicity, and 
hypersensitivity syndrome. It has recently been 
successfully used by Joshi and Mamta in 
pyoderma gangrenosum.47 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs are mainly used for joint manifestations 
of BD.2,37,48 As they are transient and follow the 
general scheme of attack and remission, and also 
as they go to remission without joint destruction 
(no sequels), no aggressive treatment is needed. 
NSAIDs have to be started at full dose and then 
tapered to a moderate dose until arthritis 
subsides. Usually, this will not take more than a 
few weeks. In case of resistant cases, especially in 
the rare chronic polyarthritis forms, disease-
modifying antirheumatic drugs (DMARDs) will 
be necessary. The best choice will be 
methotrexate with low dose prednisolone. 
Another indication of NSAIDs is EN, with or 
without joint manifestations, starting with a high 
dose and then adjusting to the need. 
For superficial phlebitis and mild forms of 
deep-vein thrombosis, DMARDs can be used, 
always starting with a high dose and then 
adjusting. 
Local treatment 
Steroids are indicated in different situations. For 
mild oral aphthosis with few attacks per year 
(less than one attack per month), systemic 
medication is not necessary. Triamcinolone in 
Orabase, an ointment that stick to the mucosa, is 
indicated if an aphthous lesion is too painful. It 
is to used in local application up to 4 times a 
day. For resistant genital aphthosis, local (in 
situ) injection of triamcinolone acetonide may 
help, but is not always efficient.2,37  
Benzoyl peroxide is an antiseptic used locally 
for genital aphthosis to accelerate the healing 
process. 
Immunosuppressive and immunomodulatory drugs 
They are used for lesions of high morbidity like 
ocular, central nervous system (CNS), vascular, 
gastrointestinal, and all other resistant 
manifestations of the disease. The main products 
used in BD are cyclophosphamide, 
chlorambucil, azathioprine, methotrexate, and 
cyclosporine. They are all to be used in 
association with prednisolone.  
In the past, cyclophosphamide for BD was 
used as oral tablets with the dose of 2-3 mg/kg 
daily. It was used in combination with 
prednisolone.49 The results in ocular 
manifestations were very interesting.48 It is now 
used in pulse therapy.50-56 Pulse 
cyclophosphamide (PCP) dose is usually 750 mg 
per square meter of body surface (around  
1000 mg), in perfusion, once monthly. It is 
combined with daily prednisolone (0.5 mg/kg). 
Once a good response is obtained, prednisolone 
is gradually tapered to the minimum dose 
maintaining the good result. After 6 monthly 
doses, pulses are given as bimonthly, then once 
every 3 months, and finally as needed (pro re 
nata or PRN). PCP is an effective treatment. 
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Good results are not due to the combined 
steroids but to PCP itself, as shown in a double 
blind control study of PCP versus placebo, 
receiving both equal doses of prednisolone.57 
Results are interesting.58,59  
Chlorambucil was one of the first cytotoxic 
drugs to be used for the treatment of 
ophthalmologic manifestations of BD.60 It is used 
as 0.2 to 0.3 mg/kg body weight. Prednisolone is 
associated as 0.5 mg/kg body weight daily. Upon 
obtaining good results, prednisolone is tapered 
gradually. In a longitudinal study on 89 patients 
with a mean follow-up duration of 26.2 ± 2.6 
months, all parameters of the eyes [mean VA, 
inflammatory index of the AU, PU, RV, and the 
total adjusted disease activity index (TADAI)] 
improved significantly.61 
Azathioprine (AZA) was used early in the 
treatment of BD.62,63 Results were not 
satisfactory because used at low dose (2 mg/kg 
daily).64 A controlled study in 1990 showed its 
effectiveness in BD.65 A more recent work, on 
2000, showed its efficacy in ocular lesions of BD, 
in 32 patients. The result of the disease activity 
index of AU, PU, the TADAI, and the mean VA 
improved significantly, but not the mean retinal 
vasculitis.66 A recent work from 2010 showed 
also good response with azathioprine, but less in 
those having retinal vasculitis.67  
Methotrexate (MTX) was first used in ocular 
manifestations of BD at a low dose of 7.5 mg 
weekly in the 199068 and 1998.69 Higher dose  
(15 mg weekly) at the beginning of the treatment 
were used later, in 2003.70 In resistant cases, doses 
up to 25 mg weekly may be used. It is mainly 
indicated in PU (mainly particularly posterior 
uveitis) . It is less efficient in RV. A longitudinal 
study of 15 years follow-up on 597 patients with 
BD (4462 eyes in the years of follow-up) showed 
an improvement of 47% of VA, an improvement 
of 89% of PU, and an improvement of 55% of 
RV.71 MTX can be used for other manifestations 
of BD, mainly for mucocutaneous and joint 
manifestations when resistant to other 
treatments.  
Cyclosporine A is an immunomodulator 
acting principally on interleukin-2 (IL-2). It is 
highly effective in transplanting organs and in 
many autoimmune diseases.1,2 Its efficacy was 
demonstrated in BD.72,73 New formulation in 
microemulsion, as we use today, was tested in 
ocular lesions with good results, where the ocular 
attacks decreased in 78.6% of patients.74 
Cyclosporine was used in pyoderma 
gangrenosum of BD74 and found, in 2003, to be 
very effective in unresponsive to other 
treatments.75 These results were later confirmed 
in 2008.76 It was also used in recurrent cutaneous 
polyarthritis nodosa-like lesions.77 However, the 
main indication is ocular lesions, especially 
uveitis.78-82 The mechanism of action has been 
broadened in BD. It has been shown , in BD 
uveitis that when combined to prednisolone, it 
down-regulates the natural killer cell-like effector 
functions of CD8brightCD56+ T cells.78 
Importantly, the production of interleukin-17, 
which plays an important role in all autoimmune 
diseases, is inhibited by cyclosporine A.82 
Cyclosporine is used as 5 mg/kg by oral route. 
As soon as a therapeutic response is obtained, the 
drug must be reduced to the minimum dose that 
keeps the patient in remission. Side effects are 
important; especially nephrotoxicity that leads to 
renal insufficiency.83 The use of cyclosporine in 
BD is associated with the occurrence of 
neurological manifestations, which appear as a 
complication of the treatment and necessitate the 
interruption of cyclosporine therapy.81-85 
All immunosuppressive drugs are efficient in 
major organ involvements of BD, mainly ocular 
manifestations.21,58,59,79,86-90 A study comparing the 
efficacy of all immunosuppressive drugs among 
1494 patients with ocular manifestations of BD 
(posterior uveitis and/or retinal vasculitis) 
followed the patients longitudinally for up to 15 
years (7685 eyes-years of treatment). It showed 
that there was no statistically significant 
difference between their efficacies on visual 
acuity. However, combination therapy of PCP  
(1 g monthly) + azathioprine (2-3 mg/kg daily) + 
prednisolone (0.5 mg/kg daily) was more 
effective on retinal vasculitis than the others. 
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Methotrexate, on the other hand, was mainly 
effective on uveitis, and had the least efficacy on 
retinal vasculitis.89 
Biological Agents 
Interferon alpha (INF-α-2a and INF-α-2b) was 
the first biological agent used for BD in 1986 by 
Tsambaos et al.91 It was first used in milder 
forms of the disease (mucocutaneous and 
articular manifestations) but the real indication 
is ocular manifestations. Kotter et al. used INF in 
high doses of 9 million international units (IU) 
daily. However, lower doses of 3 million IU 
three times a week have also used, but with 
fewer efficacies. Kotter et al. recommended to 
start the treatment with 6-9 million IU per day 
(subcutaneous injections) and to reduce the dose 
to 4.5 million IU daily after 4 weeks. After another 
4 weeks, they recommended to reduce the dose to 
3 million per day. The maintenance dose after 
complete remission will be 3 million IU three times 
per week. It is recommended to continue INF at 
least for 8 weeks after complete remission.92  
Side effects are numerous, mainly a flu-like 
syndrome necessitating the use of NSAIDs to 
overcome the reaction. The local reaction on the 
site of injection is very frequent and varies from 
a rash to pyoderma gangrenosum (although the 
latter is of exception). A case of pathergy has 
also been reported on the site of injection.93  
Results on eye lesions (from different reports) 
seem very good. Kotter et al. evaluated the 
highest number of patients (50 patients) and 
reported the response rate as 92%. The mean 
visual acuity rose from 0.46 to 0.81 after 6 
months.94 In 2006, INF was used for refractory 
cystoid macular edema with good results in 11 
out of the 15 eyes.95 In a study in 2008, only 
71.9% of the eyes responded.96 While, in another 
study in the same year, the improvement was 
88% of the eyes97 (very close to the rate reported 
by Kotter et al.94). Findings on mucocutaneous 
and articular manifestations are less impressive 
and less complete.98,99 Many recurrences are seen 
during the treatment, Kotter et al. concluded 
that INF should be reserved for more serious 
lesions of the disease like ocular lesions.94 
Anti TNF-α has recently been used in BD. 
There are sparse reports on few cases.  
Etanercept is a soluble receptor intercepting 
circulating TNF-α before it reaches its receptors on 
the cell surface. Only a double-blind, controlled 
study by Melikoglu et al. in Turkey has assessed 
the efficacy of etanercept on mucocutaneous 
lesions. Patients received 25 mg injections twice 
weekly for 3 months. There was a statistically 
significant reduction in mucocutaneous and 
articular attacks during the therapy. It is important 
to note that not all lesions responded to the 
treatment and after discontinuation, there was an 
exacerbation of attacks.100 The latter will largely 
limit the use of etanercept in treatment of BD as 
the disease is chronic and lasting for several 
decades. Melikoglu et al. also tested etanercept for 
ocular lesions in an open study on 10 cases. Patients 
were already receiving already azathioprine, 
cyclosporine, and prednisolone. All medications 
continued with the adjunction of etanercept, except 
cyclosporine. The results were not satisfactory after 
9 months of treatment since there was no 
statistically significant improvement of visual 
acuity (mean before 0.34, mean after 0.54).101  
Infliximab is a monoclonal antibody for TNF-
α. It was used by Sablé-Fourtassou et al. in 2002. 
They used it in a dosage of 5 mg/kg by infusion. 
It was given on the classic schedule of week 1, 2, 
6, 14, and then, after every 8 weeks. They used it 
in 3 patients for duration of 5 to 9 months and 
reported an excellent result. Visual acuity 
improved significantly reaching almost the 
normal value in nearly all patients. The patients 
were on INF before getting infliximab. They 
were obliged to stop it because of side effects or 
inefficacy.102 Sfikakis et al. presented the effects 
of short-term use of infliximab on uveitis in 5 
patients. The treatment response was 
dramatic.103 Many case reports have clarified the 
effects of infliximab in few patients. There are 11 
reports on 10 cases or more,104-114 all on ocular 
manifestations except one.111 Among them, only 2 
reports are on more than 20 cases.106,113 Infliximab 
is also effective in the treatment of other 
manifestations, and among them, intractable 
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gastrointestinal manifestations.115-117 Arida et al. 
reviewed 88 articles on a total of 325 cases treated 
with infliximab. They reported the improvement 
of oral ulcers 91%, genital ulcers 96%, skin lesions 
77%, erythema nodosum 81%, ocular lesions 89%, 
gastrointestinal manifestations 91%, neurological 
manifestations (central) 90%, joint manifestations 
94%, and thrombophlebitis 70%.117  
Adalimumab is a humanized anti-TNF-α 
monoclonal antibody. Arida et al. could find  
13 articles on adalimumab (on a total of 28 
patients). The results of improvement were 73% 
in oral ulcers, 86% in genital ulcers, 80% in skin 
lesions, 100% in erythema nodosum, 100% in 
ocular lesions, 100% in gastrointestinal 
manifestations, 100% in neurological 
manifestations (central), and 60% in joint 
manifestations.117 The same authors also 
reviewed 12 articles on etanercept (totally on 37 
patients) and reported improvements in 82% of 
oral ulcers, 71% of genital ulcers, 67% of skin 
lesions, 100% of erythema nodosum, 60% of ocular 
lesions,100% of neurological manifestations 
(central), and 100% of joint manifestations. 
Rituximab is an anti-CD20 antibody which 
depletes B-lymphocytes.118,119 It was used in 
connective tissue diseases and vasculitides, but 
not in BD. Recently it was used for intractable 
eye lesions of BD in one case with good 
results.120 A randomized controlled study of 
patients with intractable retinal vasculitis with 
cystoid macular edema resistant to 
immunosuppressive drugs compared rituximab 
(10 cases) with combination therapy of PCP and 
azathioprine (10 cases). Patients on rituximab 
improved while patients on immunosuppressive 
combination therapy did not.121  
As suggested by the above-mentioned 
experiences, etanercept may be partially 
effective in mucocutaneous lesions of BD but not 
much effective in ocular manifestations. 
Infliximab was effective in short- and mid-term 
studies of ocular manifestations (maximum  
3 years of follow-up in prospective studies). 
However, all the presented experiences are on 
few cases and practically short-term treatment. 
Since attacks of ocular lesions in BD continue for 
many years, it is important to have a controlled 
study on a large number of patients lasting for 
several years to judge the real efficacy of 
infliximab (as has been performed in case of 
immunosuppressive drugs). For now, the best 
indication of anti-TNF therapy will be the 
control of intractable ocular attacks, mainly the 
retinal vasculitis. Adalimumab was effective in 
the few studied cases, but only on short-term 
therapy. None of the previous studies were a 
randomized, controlled trial comparing the drug 
with a gold standard. The only study of this 
kind was with rituximab. 
How to treat patients in the daily 
practice 
It is important to keep in mind that: 1. BD 
progresses by repeated cycles of attack and 
remission, 2. not all patients with BD need 
treatment, and 3. not all of those needing 
treatment require aggressive treatment.1,2,37 The 
aim of the treatment is to: 1. accelerate the 
healing process, 2. prevent from sequels, and  
3. prolong or maintain remission.122 BD lesions 
are of two kinds: 1. Those producing some 
burden, like the majority of mucocutaneous 
lesions, joint manifestations, and some vascular 
manifestations like superficial phlebitis. For 
these lesions, complete healing is not 
indispensable. Faster healing, shorter healing 
time, fewer attacks, and longer remissions are 
sufficient. 2. Those producing high morbidity, 
like ocular manifestations, neurological 
manifestations, and the majority of vascular 
lesions especially large vein thrombosis and 
arterial aneurysm, and many of gastrointestinal 
manifestations.3,19,123 For these lesions, quick and 
complete healing along with is mandatory; 
otherwise sequels will appear. Apart quick and 
complete healing, long or definitive remission to 
prevent sequels are necessary. In case of slow 
healing process and frequent attacks, lesions 
accumulate from one attack will persist until the 
next and lead to another, leading to sever 
impairment of the involved organ. A good 
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example is eye lesions that progress toward 
sever loss of vision or blindness in few years.1 
For lesions producing some burden, the first 
line of treatment is colchicine (1 mg at bedtime). 
In case of resistance or side effects, the treatment 
is changed to levamisole. In resistant cases, 
combination of both is of help. MTX or AZA 
with low dose prednisolone, or thalidomide or 
dapson will be other choices when higher 
resistance is observed. For patients having 3 or 4 
attacks of oral aphthosis per year, there is no 
need for systemic treatment. Local treatment, in 
case of an abnormally painful attack, will 
usually suffice. The best local treatment 
(particularly Orabase) will be adequate for 
abnormally painful attacks. Pimecrolimusis 
triamcinolone in Orabase, which is an ointment 
can be used in adheres to the oral mucosa. 
Pimecrolimus ointment can be used in case of 
isolated genital aphthosis or long duration 
aphthous ulcer.124 Intralesional injection of 
triamcinolone acetonide may also be used for 
intractable genital aphthosis.  
For articular manifestations, NSAIDs for few 
to several weeks are usually sufficient. If not, 
MTX at low dose (7.5 mg weekly) + low dose 
prednisolone is the best choice. However, other 
choices can be used like levamisole, AZA, or 
cyclosporine A. 
For the second type of lesions, those with high 
morbidity, immunosuppressive drugs are 
mandatory for lesions with high morbidity. A 
short course of moderate-dose (20-30 mg/day) 
prednisolone should suffice a single for eye lesion 
(i.e. lesions, if the patient has only uveitis, and if 
uveitis is an isolated anterior uveitis). Usually 
prednisolone at moderate doses of 20 to 30 mg 
per day is largely sufficient. A short course of few 
weeks will suffice. 
However, isolated anterior uveitis is rare in 
BD. Usually the patients have a panuveitis or 
posterior uveitis alone. In these cases, the first 
line immunosuppressive drug will be MTX at  
15 mg weekly, with prednisolone 0.5 mg/kg 
daily in divided doses. After controlling the 
inflammation, the dose of prednisolone will be 
tapered gradually, every month to every 3 
months, to arrive to a maintenance dose of 7.5 mg 
weekly. It is wise to continue at this dose for 
several months before deciding to further taper 
and eventually stop the medicine. If the 
inflammation does not recur, MTX can be 
gradually tapered (by steps of 3 t0 4 months) until 
it is stopped. At each level of tapering of the drugs, 
if the inflammation recurs, and depending on its 
importance, one or several steps are taken back.  
If at the beginning of the treatment the eye does 
not respond, an escalation of drug is initiated as: 
increase of weekly dose of MTX will increase up to 
25 mg, change of MTX will be replaced with 
AZA, change to combination therapy with PCP + 
AZA + prednisolone will be prescribed. 
Inefficacy of all these methods will necessitate the 
substitution of immunosuppressive + AZA + 
prednisolone as described before. If still no 
benefit, change of immunosuppressive strategy 
with to biological agents. 
If eye lesions are retinal vasculitis, with or 
without posterior uveitis, the first line of 
treatment will be combination therapy with PCP 
+ AZA + prednisolone (0.5 mg/kg daily). After 
controlling the inflammation, prednisolone dose 
will be tapered gradually, every month to every 
3 months, to arrive to a maintenance dose of  
7.5 mg daily. If the inflammation does not recur 
after 6 PCP, the rhythm of once monthly pulse is 
decreased to once every two months and then to 
once every 3 months. If still in remission, PCP 
will be stopped after 3 to 4 PCP, and the patient 
will continue on AZA alone. After several 
months at this regimen, the tapering will start 
again with prednisolone, exactly as for uveitis 
alone, and then with AZA.  
At any step, if the inflammation recurs, the 
treatment will get one to several steps 
depending on the importance of the new attack. 
If the combination does not work, AZA can be 
changed to MTX or to cyclosporine A. If still no 
improvement, biological agents have to start, if 
the patient can afford it. 
For neurological manifestations, the same 
treatment scheme as for retinal vasculitis is used, 
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except prednisolone is to be given as 1 mg/kg 
daily. In case of treatment escalation and change of 
immunosuppressive drugs, cyclosporine is to be 
avoided, because of its neurological side effects. 
For vascular involvement, the classic strategy 
was the prescription of anticoagulants. However, 
new experiences and papers are more and more in 
favor of immunosuppressive drugs  
+ prednisolone for these cases. Depending on the 
site and the form of the lesion, anticoagulation 
may be given, but not for longtime as in the 
past.125-129 Ahn et al. demonstrated that adding 
anticoagulants did not improve the results 
obtained by immunosuppressive drugs  
+ prednisolone in deep vein thrombosis.126 
However, for superficial vein thrombosis and 
some restricted and mild forms of deep vein 
thrombosis, NSAIDs may be enough. In such 
cases, trying NSAIDs before opting for the 
aggressive treatment will be beneficial. 
For gastrointestinal manifestations, the first 
treatment to try is sulfasalazine (2 g daily) + 
prednisolone in low to moderate doses. If not 
sufficient, immunosuppressive drugs are 
necessary. In case of resistance to the treatment, 
biological agents are the last resort. 
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